| Description | LY341495 is a potent metabotropic glutamate receptor antagonist that exhibits high activity against a wide range of glutamate receptor subtypes and can be used for the study of neurological disorders. |
| In vivo | 急性给药 LY341495 (3.0 mg/kg)可降低 pAkt 和 pGSK-3 水平，但需要反复给药(3.0 mg/kg)才能降低 b-连环蛋白水平[2]。 |
| Target activity | mGluR1a:7.8 μM, mGluR8:170 nM, mGluR2:21 nM, mGluR7:990 nM, 21 nM:mGluR3 |
| molecular weight | 353.37 |
| Molecular formula | C20H19NO5 |
| CAS | 201943-63-7 |
| Storage | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | DMSO: 5 mg/mL (14.15 mM), Sonication is recommended. H2O: < 0.1 mg/mL (insoluble) |
| References | 1. Pitsikas N, et al. The metabotropic glutamate 2/3 receptor antagonist LY341495 differentially affects recognition memory in rats. Behav Brain Res. 2012 May 1;230(2):374-9. 2. Sutton LP, et al. Regulation of Akt and Wnt signaling by the group II metabotropic glutamate receptor antagonist LY341495 and agonist LY379268.J Neurochem. 2011 Jun;117(6):973-83. 3. Linden AM, et al. Use of MGLUR2 and MGLUR3 knockout mice to explore in vivo receptor specificity of the MGLUR2/3 selective antagonist LY341495. Neuropharmacology. 2009 Aug;57(2):172-82. Epub 2009 May 27. 4. Li J, et al. N-acetyl-cysteine attenuates neuropathic pain by suppressing matrix metalloproteinases. Pain. 2016 Aug;157(8):1711-23. |